Captis diagnostics - sbir concept award - development of non-invasive assay for molecular characterization of pediatric low-grade glioma
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91022C00005
- Awardee
-
Captis Diagnostics Inc. UEI JS3HJ4EHJ9J8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $354,637
Award facts
- Opportunity
-
- National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Concept Award Program – Fiscal Year 2022 Pre-Solicitation · 75N91020R00043 · Posted Jul 10, 2020
- Contract value 100% obligated
- $354,637.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 46 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15213, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $55,000 | |
| Original award | $299,637 |
About this award
Captis Diagnostics Inc. was awarded a $354,637 firm fixed price definitive contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. This contract is a Phase I Small Business Innovation Research Concept Award to develop a non-invasive assay for molecular characterization of pediatric low-grade glioma. The work will be performed in Pittsburgh, Pennsylvania over a period of approximately two years ending in July 2024. This award was made under a total small business set-aside solicitation seeking innovative concepts for pediatric and rare cancer therapies, diagnostics or preventative strategies, with a focus on technical feasibility and proof-of-concept. Captis Diagnostics will enhance its entrepreneurship skills and develop a commercialization plan as part of this Concept Award, which could provide a pipeline to future SBIR funding to advance the proposed product.
Quick answers
Who was awarded contract 75N91022C00005?
75N91022C00005 was awarded to Captis Diagnostics Inc. by National Cancer Institute (National Institutes of Health) on January 19, 2022.
How much is contract 75N91022C00005 worth?
The government has obligated $354,637 on 75N91022C00005.
Was contract 75N91022C00005 competed?
The extent of competition for 75N91022C00005 was full and open competition after exclusion of sources. The government received 46 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award